The Size of the Latin America Stem Cell Assay Market is valued at USD 93.85 Million in 2020 and is estimated to be growing at a CAGR of 20.1%, to reach USD 234.51 Million by 2025 during the forecast period 2020-2025.
With the increase in new developments in the research on stem cells such as stem cell plasticity, controversies are also increasing. The research on stem cells is required to be guided by a specific set of guidelines and definitions and hence the use of stem cell assays is increasing rapidly.
There are numerous stem cell assays available in the market and they can be used to assess the potency of stem cells. Also, to justify the functionality of stem cells, more than one assay has to be used on a single batch of stem cells. Stem cells have many uses for humans. For instance, Stem cells obtained from adult blood and bone marrow can be used to treat blood diseases like leukemia.
Rising expenditure on stem cell research to develop advanced therapies, Increase in aging population and chronic diseases are the major factors driving the stem cell assay market. The application of stem cells in drug testing by using drugs on tissues produced from stem cells is also expected to drive the market. Enormous costs related to the use of stem cell therapy as well as conducting research are restricting the market.
Latin America Stem Cell Assay Market has been segmented and sub-segmented into the following categories.
On the basis of region, developing countries like Brazil and Argentina with huge patient base provide a lot of opportunities for the expansion of companies in this region.
Key Market Companies dominating the Latin America Stem Cell Assay Market Profiled in the Report are Thermo Fisher Scientific Inc., Bio-Techne Corporation, Stem cell Technologies Inc., Merck KGaA, Promega Corporation, GE Healthcare, Bio-Rad Laboratories, Inc., Cellular Dynamics International Inc., Hemogenix, and Cell Biolabs Inc.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemiology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Assay Type
5.1.1 Introduction
5.1.2 Cell Viability & Toxicity Assays
5.1.3 Cell Identification Assays
5.1.4 Cell Differentiation Assays
5.1.5 Isolation/Purification Assays
5.1.6 Cell Proliferation Assays
5.1.7 Cell Apoptosis Assays
5.1.8 Cell Function Assays
5.1.9 Y-o-Y Growth Analysis, By Assay Type
5.1.10 Market Attractiveness Analysis, By Assay Type
5.1.11 Market Share Analysis, By Assay Type
5.2 Technology
5.2.1 Introduction
5.2.2 Technology Roadmap
5.2.3 Micro Fabricated Assisted Technology
5.2.3.1 Microfluidics Based Cell Trap Technologies
5.2.4 Technology in Development
5.2.5 Y-o-Y Growth Analysis, By Technology
5.2.6 Market Attractiveness Analysis, By Technology
5.2.7 Market Share Analysis, By Technology
5.3 Kits
5.3.1 Introduction
5.3.2 Adult Stem Cell Kits
5.3.2.1 Induced Pluripotent Stem Cell Kits
5.3.2.2 Mesenchymal Stem Cell Kits
5.3.2.3 Neuronal Stem Cells Kits
5.3.2.4 Umbilical Cord Stem Cells
5.3.2.5 Hematopoietic Stem Cell Kits
5.3.3 Human Embryonic Stem Cells Kits
5.3.4 Y-o-Y Growth Analysis, By Kits
5.3.5 Market Attractiveness Analysis, By Kits
5.3.6 Market Share Analysis, By Kits
5.4 Product
5.4.1 Introduction
5.4.2 Instruments
5.4.2.1 Micro Electrode Arrays
5.4.2.2 Cell Imaging Systems
5.4.2.3 Automated Cell Counter
5.4.2.4 Flow Cytometer
5.4.3 Detection Kits
5.4.3.1 Immuno Histochemistry Kits
5.4.4 Y-o-Y Growth Analysis, By Product
5.4.5 Market Attractiveness Analysis, By Product
5.4.6 Market Share Analysis, By Product
5.5 Application
5.5.1 Introduction
5.5.2 Regenerative Medicine & Therapy Development
5.5.2.1 Orthopedic & Musculoskeletal Spine
5.5.2.2 Central Nervous System
5.5.2.3 Dermatology
5.5.2.4 Cardiovascular
5.5.2.5 Diabetes
5.5.2.6 Oncology
5.5.2.7 Others
5.5.3 Drug Discovery and Development
5.5.4 Clinical Research
5.6 End User
5.6.1 Introduction
5.6.2 Research Institutes
5.6.3 Industry Research
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Assay Type
6.1.3.3 By Technology
6.1.3.4 By Kits
6.1.3.5 By Product
6.1.3.6 By Application
6.1.3.7 By End User
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Assay Type
6.1.4.3 By Technology
6.1.4.4 By Kits
6.1.4.5 By Product
6.1.4.6 By Application
6.1.4.7 By End User
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Assay Type
6.1.5.3 By Technology
6.1.5.4 By Kits
6.1.5.5 By Product
6.1.5.6 By Application
6.1.5.7 By End User
6.2 Brazil
6.3 Mexico
6.4 Rest of Latin America
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Thermo Fisher Scientific Inc.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Bio-Techne Corporation
8.3 STEMCELL Technologies Inc.
8.4 Promega Corporation
8.5 GE Healthcare
8.6 Bio-Rad Laboratories, Inc.
8.7 Merck KGaA
8.8 Cellular Dynamics International Inc.
8.9 Hemogenix
8.10 Cell Biolabs Inc.
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, Collaborations, and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Feb 2020
